BICC1

Across TCGA pan-cancer cohorts, BICC1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BICC1 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BICC1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BICC1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where BICC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.461	0.690	.003	27	view →
LSCC	DFS	Tertile	II,III,IV	0.577	0.855	.009	19	view →
CCRCC	OS	Median	IV	0.150	0.785	.040	4	view →
HNSC	DFS	Tertile	III,IV	0.868	0.669	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BICC1–PDAC (OS)

Open the PDAC breakdown →